{"organizations": [], "uuid": "61fdcaa256e387e19774f21f97730f4a7ebc3c06", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180130.html", "section_title": "Archive News &amp; Video for Tuesday, 30 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-revive-therapeutics-advances-resea/brief-revive-therapeutics-advances-research-program-of-cannabinoid-based-therapies-targeting-liver-diseases-idUSFWN1PP0SY", "country": "US", "domain_rank": 408, "title": "BRIEF-Revive Therapeutics Advances Research Program Of Cannabinoid-Based Therapies Targeting Liver Diseases", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.654, "site_type": "news", "published": "2018-01-30T20:04:00.000+02:00", "replies_count": 0, "uuid": "61fdcaa256e387e19774f21f97730f4a7ebc3c06"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-revive-therapeutics-advances-resea/brief-revive-therapeutics-advances-research-program-of-cannabinoid-based-therapies-targeting-liver-diseases-idUSFWN1PP0SY", "ord_in_thread": 0, "title": "BRIEF-Revive Therapeutics Advances Research Program Of Cannabinoid-Based Therapies Targeting Liver Diseases", "locations": [], "entities": {"persons": [{"name": "sanyal", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-revive therapeutics advances research program", "sentiment": "negative"}, {"name": "therapeutics ltd", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 30 (Reuters) - Revive Therapeutics Ltd:\n* REVIVE THERAPEUTICS ADVANCES RESEARCH PROGRAM OF CANNABINOID-BASED THERAPIES TARGETING LIVER DISEASES\n* REVIVE THERAPEUTICS LTD - RESEARCH WILL BE OVERSEEN BY SANYAL BIOTECHNOLOGY LLC COMPANYâ€˜S STRATEGIC RESEARCH PARTNER FOR LIVER DISEASES Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-30T20:04:00.000+02:00", "crawled": "2018-01-31T16:33:52.017+02:00", "highlightTitle": ""}